GSK buys full rights to make COVID, influenza vaccines from CureVac
Wednesday, July 3rd 2024, 6:25:52 am
article
The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
Breaking
The crash came in the middle of one of the most important nights on the Chabad calendar, startling thousands of...
President Donald Trump’s Tuesday speech in Iowa made one thing abundantly clear: it is urgent that we get American energy policy right....
The agency says issuer approval is required for true tokenized ownership, warning that many stock tokens sold to retail investors provide only indirect or synthetic exposure.
...
